Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort
This study found that SGC therapy may increase adverse reactions and HCRU in IgAN patients, while comparatively providing no beneficial effects on preserving kidney function.
Authors
- Mit Patel
- Gaëlle Gusto
- Giancarlo Pesce (ORCID: https://orcid.org/0000-0003-4925-6325)
- Terri Madison
- Aastha Chandak (ORCID: https://orcid.org/0000-0001-5653-435X)
- Ananth Kadambi (ORCID: https://orcid.org/0000-0002-5669-4887)
Institutions
- Health Economics and Outcomes Research (United Kingdom) (GB)
- IQ Solutions (US)
Publication Details
- Journal
- Frontiers in Nephrology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3389/fneph.2025.1574239
- Citations
- 1
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.82